HC Wainwright Reiterates “Buy” Rating for Abeona Therapeutics (NASDAQ:ABEO)

HC Wainwright reaffirmed their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research report report published on Monday morning,Benzinga reports. The firm currently has a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.16) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.17) EPS.

Several other brokerages have also recently weighed in on ABEO. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th.

Abeona Therapeutics Price Performance

Shares of ABEO stock opened at $6.41 on Monday. Abeona Therapeutics has a twelve month low of $3.05 and a twelve month high of $9.01. The stock has a market capitalization of $278.64 million, a price-to-earnings ratio of -2.39 and a beta of 1.52. The stock has a fifty day simple moving average of $6.22 and a two-hundred day simple moving average of $5.32. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC acquired a new position in Abeona Therapeutics during the 1st quarter valued at about $91,000. Jane Street Group LLC acquired a new position in Abeona Therapeutics during the 3rd quarter valued at about $84,000. Charles Schwab Investment Management Inc. acquired a new position in Abeona Therapeutics during the 3rd quarter valued at about $151,000. XTX Topco Ltd acquired a new position in Abeona Therapeutics during the 3rd quarter valued at about $160,000. Finally, GSA Capital Partners LLP increased its position in Abeona Therapeutics by 54.3% during the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 33,831 shares in the last quarter. 80.56% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.